Standard
Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis. / Schwartz, Brian; Schou, Morten; Barrillas Lara, Irene Maria; Monahan, Kevin; Helm, Robert; Køber, Lars; Gislason, Gunnar H.; Ramachandran, Vasan S.; Torp-Pedersen, Christian; Andersson, Charlotte.
I:
Heart Rhythm O2, Bind 3, Nr. 4, 2022, s. 430-432.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Schwartz, B
, Schou, M, Barrillas Lara, IM, Monahan, K, Helm, R
, Køber, L, Gislason, GH, Ramachandran, VS, Torp-Pedersen, C & Andersson, C 2022, '
Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis',
Heart Rhythm O2, bind 3, nr. 4, s. 430-432.
https://doi.org/10.1016/j.hroo.2022.04.008APA
Schwartz, B.
, Schou, M., Barrillas Lara, I. M., Monahan, K., Helm, R.
, Køber, L., Gislason, G. H., Ramachandran, V. S., Torp-Pedersen, C., & Andersson, C. (2022).
Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis.
Heart Rhythm O2,
3(4), 430-432.
https://doi.org/10.1016/j.hroo.2022.04.008Vancouver
Schwartz B
, Schou M, Barrillas Lara IM, Monahan K, Helm R
, Køber L o.a.
Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis.
Heart Rhythm O2. 2022;3(4):430-432.
https://doi.org/10.1016/j.hroo.2022.04.008Author
Schwartz, Brian ; Schou, Morten ; Barrillas Lara, Irene Maria ; Monahan, Kevin ; Helm, Robert ; Køber, Lars ; Gislason, Gunnar H. ; Ramachandran, Vasan S. ; Torp-Pedersen, Christian ; Andersson, Charlotte. / Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis. I: Heart Rhythm O2. 2022 ; Bind 3, Nr. 4. s. 430-432.
Bibtex
@article{9a34a2e8d0ff4d43ab70f7cce2fb7449,
title = "Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis",
keywords = "Atrial fibrillation, Epidemiology, Heart failure, Mortality, Survival",
author = "Brian Schwartz and Morten Schou and {Barrillas Lara}, {Irene Maria} and Kevin Monahan and Robert Helm and Lars K{\o}ber and Gislason, {Gunnar H.} and Ramachandran, {Vasan S.} and Christian Torp-Pedersen and Charlotte Andersson",
note = "Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584 . Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine . Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584. Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Schou has received lecture fees from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk that are unrelated to the present work. Dr K{\o}ber reports lecture fees from Novartis, BMS, and AstraZeneca that are unrelated to the present work. Dr Torp-Pedersen has received study funding from Bayer and Novo Nordisk that is unrelated to the present work. All other authors declare that they have no conflicts of interest. All authors attest they meet the current ICMJE criteria for authorship. Consent was waived due ot the use of de-identified data. This study was exempted from ethical board approval, as the data from the registry used in this study were de-identified.",
year = "2022",
doi = "10.1016/j.hroo.2022.04.008",
language = "English",
volume = "3",
pages = "430--432",
journal = "Heart Rhythm O2",
issn = "2666-5018",
publisher = "Elsevier",
number = "4",
}
RIS
TY - JOUR
T1 - Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis
AU - Schwartz, Brian
AU - Schou, Morten
AU - Barrillas Lara, Irene Maria
AU - Monahan, Kevin
AU - Helm, Robert
AU - Køber, Lars
AU - Gislason, Gunnar H.
AU - Ramachandran, Vasan S.
AU - Torp-Pedersen, Christian
AU - Andersson, Charlotte
N1 - Funding Information:
Dr Schwartz was funded by NIH StARR Grant 1R38HL143584 . Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine .
Funding Information:
Dr Schwartz was funded by NIH StARR Grant 1R38HL143584. Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Schou has received lecture fees from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk that are unrelated to the present work. Dr Køber reports lecture fees from Novartis, BMS, and AstraZeneca that are unrelated to the present work. Dr Torp-Pedersen has received study funding from Bayer and Novo Nordisk that is unrelated to the present work. All other authors declare that they have no conflicts of interest. All authors attest they meet the current ICMJE criteria for authorship. Consent was waived due ot the use of de-identified data. This study was exempted from ethical board approval, as the data from the registry used in this study were de-identified.
PY - 2022
Y1 - 2022
KW - Atrial fibrillation
KW - Epidemiology
KW - Heart failure
KW - Mortality
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85131119483&partnerID=8YFLogxK
U2 - 10.1016/j.hroo.2022.04.008
DO - 10.1016/j.hroo.2022.04.008
M3 - Journal article
C2 - 36097453
AN - SCOPUS:85131119483
VL - 3
SP - 430
EP - 432
JO - Heart Rhythm O2
JF - Heart Rhythm O2
SN - 2666-5018
IS - 4
ER -
